Why Did SoFi Stock Drop?
Fintech platform SoFi (NASDAQ:SOFI) has stumbled in recent days, selling…
Buy
56
IVBXF Quote, Financials, Valuation and Earnings
Last price:
$11.16
Seasonality move
:
5.88%
Day range:
$11.79 - $11.89
52-week range:
$3.91 - $15.12
Dividend yield:
0%
P/E ratio:
126.50x
P/S ratio:
12.41x
P/B ratio:
10.65x
Volume:
11.7K
Avg. volume:
3.3K
1-year change:
143.9%
Market cap:
$20.2B
Revenue:
$1.3B
EPS (TTM):
$0.10
Analysts' Opinion
-
Consensus RatingNo consensus rating exists at this time due to lack of analyst coverage.
-
Price Target DownsideNo price target exists because of limited analyst coverage.
-
Price Target UpsideSimilarly, at this time, analysts have not provided a price target so downside risk can't be assessed accurately at this time.
Fair Value
-
According to the consensus of 0 analysts, Innovent Biologics, Inc. has -- downside to fair value with a price target of -- per share.
IVBXF vs. S&P 500
-
Over the past 5 trading days, Innovent Biologics, Inc. has underperformed the S&P 500 by -2.9% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Innovent Biologics, Inc. does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Innovent Biologics, Inc. has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Innovent Biologics, Inc. reported revenues of --.
Earnings Growth
-
Innovent Biologics, Inc. has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Innovent Biologics, Inc. reported earnings per share of --.
Enterprise value:
18.5B
EV / Invested capital:
--
Price / LTM sales:
12.41x
EV / EBIT:
--
EV / Revenue:
14.09x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-317.07x
Price / Operating cash flow:
142.55x
Enterprise value / EBITDA:
324.80x
Gross Profit (TTM):
$1.4B
Return On Assets:
-0.46%
Net Income Margin (TTM):
9.89%
Return On Equity:
-0.75%
Return On Invested Capital:
-0.6%
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-12-08 | 2024-12-08 | 2024-12-08 | |||
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -- | -- | -- | -- | -- | |
| EBITDA | -- | -- | -- | -- | -- | |
| Diluted EPS | -- | -- | -- | -- | -- | |
| Period Ending | 2021-06-30 | 2022-06-30 | 2023-06-30 | 2024-06-30 | 2025-06-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $2.1B | $1.7B | $1.6B | $1.5B | -- | |
| Total Assets | $2.5B | $2.4B | $2.5B | $2.8B | -- | |
| Current Liabilities | $346.7M | $519.5M | $396M | $567.9M | -- | |
| Total Liabilities | $704M | $980M | $980.7M | $1.1B | -- | |
| Total Equity | $1.8B | $1.4B | $1.5B | $1.7B | -- | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-12-08 | 2024-12-08 | 2024-12-08 | |||
| Cash Flow Statement | ||||||
| Cash Flow Operations | -- | -- | -- | -- | -- | |
| Cash From Investing | -- | -- | -- | -- | -- | |
| Cash From Financing | -- | -- | -- | -- | -- | |
| Free Cash Flow | -- | -- | -- | -- | -- | |
IVBXF
Sector
Market Cap
$20.2B
$28.5M
Price % of 52-Week High
77.98%
51.44%
Dividend Yield
0%
0%
Shareholder Yield
-0.06%
-1.33%
1-Year Price Total Return
143.9%
-20.32%
Beta (5-Year)
0.084
0.520
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$12.16
200-day SMA
Buy
Level
$9.60
Bollinger Bands (100)
Sell
Level
11.33 - 12.73
Chaikin Money Flow
Buy
Level
2.6M
20-day SMA
Buy
Level
$11.73
Relative Strength Index (RSI14)
Buy
Level
50.25
ADX Line
Buy
Level
15.22
Williams %R
Neutral
Level
-58.6941
50-day SMA
Buy
Level
$11.67
MACD (12, 26)
Buy
Level
0.19
25-day Aroon Oscillator
Buy
Level
88
On Balance Volume
Neutral
Level
1.9M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (3.8812)
Buy
CA Score
(Annual)
Level (0.2333)
Sell
Beneish M-Score
(Annual)
Level (-2.0647)
Buy
Momentum Score
Level (10)
Sell
Ohlson Score
Level (4.1828)
Buy
Piotroski F Score
(Annual)
Level (7)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Innovent Biologics, Inc. is a biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases. It operates through the following geographical segments: The People's Republic of China (PRC), the United States of America (USA), and Indonesia. The company was founded by De Chao Yu, Kevin Chen, and Scott M. Wheelwright on April 28, 2011 and is headquartered in Suzhou, China.
Stock Forecast FAQ
In the current month, IVBXF has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The IVBXF average analyst price target in the past 3 months is --.
-
Where Will Innovent Biologics, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Innovent Biologics, Inc. share price will drop to -- per share over the next 12 months.
-
What Do Analysts Say About Innovent Biologics, Inc.?
Analysts are divided on their view about Innovent Biologics, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Innovent Biologics, Inc. is a Sell and believe this share price will rise from its current level to --.
-
What Is Innovent Biologics, Inc.'s Price Target?
The price target for Innovent Biologics, Inc. over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is IVBXF A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Innovent Biologics, Inc. is a --. 0 of 0 analysts rate the stock a -- at this time.
-
How Can I Buy Shares Of IVBXF?
You can purchase shares of Innovent Biologics, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Innovent Biologics, Inc. shares.
-
What Is The Innovent Biologics, Inc. Share Price Today?
Innovent Biologics, Inc. was last trading at $11.16 per share. This represents the most recent stock quote for Innovent Biologics, Inc.. Yesterday, Innovent Biologics, Inc. closed at $11.79 per share.
-
How To Buy Innovent Biologics, Inc. Stock Online?
In order to purchase Innovent Biologics, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get IVBXF Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
IVBXF
Sector
P/E ratio
126.50x
23.75x
PEG ratio
--
-0.01x
P/B ratio
10.65x
1.83x
Price / LTM sales
12.41x
1.60x
Growth Metrics
IVBXF
Sector
Revenue growth
--
4.85%
Earnings growth
--
11.11%
Revenue (5-year growth)
53.91%
6.45%
Earnings forecast
--
-$0.20
Profitability
IVBXF
Sector
Profitability FY 2024
$1.1B
$3.6M
Return on invested capital
-0.6%
-30.98%
Return on assets
-0.46%
-27.62%
Return on equity
-0.75%
-36.69%
Earnings Date
Last Earnings Date
Aug
27
Next Earnings Date
Mar
24
Estimated Next Earnings Date
Nov
26
Balance Sheet
IVBXF
Sector
Total cash
$1.1B
$27.2M
Short term investments
$51.4M
$25.7M
Total assets
$3B
$79.7M
Long term debt
--
$4.1M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will Robinhood Win AI Investing?
Recently, online brokerage Robinhood (NASDAQ:HOOD) has been focused on introducing…
Is Amazon an AI Stock?
With the market starting to look skittish on pure-play AI…
Stock Ideas
Buy
52
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 62x
Buy
56
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 37x
Buy
81
Is GOOG Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 40x
Alerts
Buy
56
SMX alert for Dec 8
SMX (Security Matters) Plc [SMX] is down 66.41% over the past day.
Buy
62
PRAX alert for Dec 8
Praxis Precision Medicines, Inc. [PRAX] is up 9.56% over the past day.
Sell
13
PSN alert for Dec 8
Parsons Corp. [PSN] is down 5.46% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
